Other Work

Pending/submitted projects

PO1# 1610406 (resubmission) Overall PI: Feldman A and Scott D. 09/19/2024–8/30/2029
Molecular Diagnosis, Prognosis, and Therapeutic Targets in Lymphoma
DHHS/NIH/NCI
Project 3 PI (Iqbal) – Molecular Pathogenesis of two newly defined n-TFHLs
We will perform extensive genomic characterization of these novel PTCL subgroups, generate genetically faithful murine models and develop patient-derived xenograft models for novel therapeutic approaches in PTCL.

Completed projects

5PO1CA229100: Overall PI: Liza Rimsza 09/19/2018–8/30/2023 (NCE)
Funding: DHHS/NIH/NCI
Molecular Pathogenesis of two newly defined major subgroups of PTCL Peripheral T-cell lymphoma (PTCL) is a heterogenous group of lymphomas with 30-50% remains unclassifiable (PTCL-NOS). We have delineated two novel biological and prognostic subgroups within PTCL-NOS. We performed extensive genomic characterization of these novel PTCL subgroups, generated genetically faithful murine models and developed patient-derived xenograft models for novel therapeutic approaches in PTCL. (Co-PI: Iqbal, Chan)

NE DHHS – LB506 (Iqbal) 07/01/2021–06/30/2022
Delineating epigenetic reprogramming in Angioimmunoblastic T-cell lymphoma using murine models
Developed triple mutant murine models (TET2, IDH2R172K and DNMT3A) to delineate the role of epistasis mutations in T-cell pathogenesis.

Roswell Park Cancer Institute Fu (PI)
Targeting PLK-1 for Treating MYC-Driven Lymphomas
Identified the role of PLK1 in upregulating MYC expression in aggressive lymphomas.

Industry-sponsored projects
Kymera Therapeutics, Inc. (Iqbal)
Therapeutic efficacy of degrading Stat3 in PTCLs

Leidos Biomedical Research, Inc. (Iqbal). 08/14/2020–06/30/2023
Subcontract with Leidos Biomedical Research 19X121Q TCGA-like sequencing project (PTCLs n=500).
Performed high-throughput genomic sequencing on well-characterized PTCL cases collected over several clinical centers.

5UH3CA206127-04 (Iqbal) 04/01/2017–08/31/2022 (NCE) 1.20 calendar
DHHS/NIH/NCI
Translated the diagnostic and prognostic signatures for PTCL into a platform that can be used robustly on paraffin-embedded tissue in routine clinical practice and clinical trials.
Molecular diagnostic signatures for PTCL

NE DHHS – LB506 (#22051) Iqbal (PI) 2018–2019
Role of Epigenomic Modifiers in AITL pathogenesis (tumor microenvironment)

2021-05 (Bhatt). 2020–2021
NE DHHS – LB506
ONC201 maintenance after hematopoietic stem cell transplant
Monitored NK cell gene expression changes post HSCT and ONC201 treated AML patients.

UN Foundation Iqbal (PI) 2018–2019
Role of Concurrent Loss of TET2 Function and Neomorphic Activity in IDH2 in the AITL Pathogenesis

R41CA221466-01A1 Morris S/Iqbal (MPI) 2018–2019
Development of a Novel Clinical Diagnostic Assay for Peripheral T-cell Lymphoma (PTCL)

Lymphoma Research Foundation (LRF) Iqbal (PI) 2013–2015
Somatic mutations in the pathogenesis of angioimmunoblastic T- cell lymphoma (AITL)
Identified mutations that are involved in pathogenesis of AITL.

Leukemia & Lymphoma Society (LLS: The Translational Research Program) Iqbal (PI) 2013–2016
Somatic mutations and epimutations in Peripheral T-cell Lymphoma
Performed next-generation sequencing in PTCLs to identify driver mutations.

NTSBRDF Iqbal (PI) 2013–2014
Synergism of PRDM1 Loss and LMP1 Expression in NK cell Lymphoma genesis

U01-CA-114778-05 Chan (PI) 2005–2010
Molecular Signatures to Improve Diagnosis and Outcome Prediction in NHL
Identified molecular signatures for major B-cell lymphomas.
Role: Co-Investigator